MNMD Projected Dividend Yield
Mind Medicine Mindmed Inc ( NASDAQ : MNMD )Mind Medicine Mindmed is a clinical stage biopharmaceutical company developing products to treat brain health disorders, with a focus on psychiatry, addiction, pain and neurology. Co.'s drug candidates include: MM-120, which is a proprietary, pharmaceutically optimized form of lysergide, and is being developed for the treatment of generalized anxiety disorder; MM-110, which is its proprietary form of 18-methoxycoronaridine, a congener of ibogaine, that is being developed for the treatment of opioid withdrawal; and MM-402, which is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine, that is developed for the treatment of main symptoms of autism spectrum disorder. 21 YEAR PERFORMANCE RESULTS |
MNMD Dividend History Detail MNMD Dividend News MNMD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |